Compare Under Armour Inc Class A (UAA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs State Street SPDR S&P Biotech ETF — how do they compare? Under Armour Inc Class A trades at $4.96 (market cap $2.07B), while State Street SPDR S&P Biotech ETF trades at $154.01 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.9× Under Armour Inc Class A's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| UAA | XBI | |
|---|---|---|
Market Cap | $2.07B | $10.11B |
Volume | 12,050,442 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $8.14 | $169.55 |
52-Week Low | $4.17 | $104.99 |
Typical Hold Time | 99 Days | — |
Enterprise Value | $3.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UAA) trades at $4.94, up 2.49% today, as the company navigates a challenging turnaround. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while technical indicators show a bullish trend despite negative profitability metrics. The company faces revenue declines but maintains margin improvement focus, with analyst consensus leaning toward Hold amid ongoing transformation efforts.
The outlook remains cautious with revenue weakness offset by cost discipline. Investment opportunity exists if margin gains translate to sustained profitability, but risks include persistent demand softness and high debt levels. Current valuation appears reasonable with P/S of 0.42, though negative ROE and net margins warrant careful monitoring of the brand transformation progress.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
